Cornerstone Capital Inc. trimmed its stake in Amgen Inc. (NASDAQ:AMGN – Free Report) by 1.9% during the third quarter, Holdings Channel.com reports. The fund owned 89,199 shares of the medical research company’s stock after selling 1,725 shares during the period. Amgen accounts for about 3.3% of Cornerstone Capital Inc.’s investment portfolio, making the stock its 10th biggest position. Cornerstone Capital Inc.’s holdings in Amgen were worth $37,598,000 at the end of the most recent reporting period.
Several other large investors have also recently made changes to their positions in the stock. State Street Corp grew its position in Amgen by 38.2% in the 2nd quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock valued at $15,283,363,000 after acquiring an additional 11,656,755 shares in the last quarter. MW Advisory LLC purchased a new stake in Amgen during the second quarter worth about $1,054,000. Baird Financial Group Inc. increased its stake in Amgen by 1.6% during the second quarter. Baird Financial Group Inc. now owns 339,825 shares of the medical research company’s stock worth $123,057,000 after purchasing an additional 5,496 shares during the period. MassMutual Private Wealth & Trust FSB lifted its position in shares of Amgen by 105.8% during the third quarter. MassMutual Private Wealth & Trust FSB now owns 13,514 shares of the medical research company’s stock worth $5,696,000 after purchasing an additional 6,947 shares in the last quarter. Finally, Nilsine Partners LLC acquired a new stake in shares of Amgen during the second quarter worth about $3,329,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.
Amgen Price Performance
Shares of NASDAQ AMGN opened at $462.32 on Tuesday. The stock’s 50-day moving average is $425.81 and its two-hundred day moving average is $381.77. The company has a debt-to-equity ratio of 3.60, a current ratio of 1.48 and a quick ratio of 1.20. Amgen Inc. has a 1-year low of $312.39 and a 1-year high of $483.99. The company has a market cap of $250.07 billion, a price-to-earnings ratio of 26.82, a price-to-earnings-growth ratio of 3.25 and a beta of 0.43.
Amgen (NASDAQ:AMGN – Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.79 by $0.66. The business had revenue of $10.37 billion during the quarter, compared to analysts’ expectations of $10.07 billion. Amgen had a return on equity of 114.99% and a net margin of 24.14%. The business’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same quarter last year, the business posted $5.64 EPS. Analysts forecast that Amgen Inc. will post 23.37 EPS for the current fiscal year.
Amgen Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Friday, November 20th will be paid a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Friday, November 20th. Amgen’s dividend payout ratio is presently 58.47%.
Analyst Upgrades and Downgrades
Several research analysts have recently commented on AMGN shares. Citigroup raised their price objective on shares of Amgen from $405.00 to $465.00 and gave the company a “neutral” rating in a research note on Wednesday, November 4th. TD Cowen upped their target price on shares of Amgen from $452.00 to $531.00 and gave the stock a “buy” rating in a research note on Wednesday, November 4th. Wall Street Zen raised shares of Amgen from a “hold” rating to a “buy” rating in a research note on Sunday, October 18th. Oppenheimer reiterated an “outperform” rating on shares of Amgen in a report on Friday, October 23rd. Finally, Morgan Stanley raised their price target on shares of Amgen from $359.00 to $410.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eighteen have given a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Amgen has a consensus rating of “Hold” and a consensus price target of $425.69.
View Our Latest Analysis on Amgen
About Amgen
Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.
Recommended Stories
- Five stocks we like better than Amgen
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
